The Lancet Oncology, Volume 14, Issue 10, Pages 913 - 914, September 2013
doi:10.1016/S1470-2045(13)70385-1
Cite or Link Using DOI
Cite or Link Using DOICopyright © 2013 Elsevier Ltd All rights reserved.
Icotinib: kick-starting the Chinese anticancer drug industry
In The Lancet Oncology , Yuankai Shi and colleagues 1 report the results of ICOGEN—a non-inferiority study of icotinib versus gefitinib for advanced non-small-cell lung cancer—and provide phase 3 evidence supporting the use of this first-generation (reversible, non-mutation-specific) EGFR tyrosine kinase inhibitor (TKI).
Icotinib is an interesting drug, not only medically, but also politically. It seems to be no better than other first-generation drugs in terms of efficacy—the median progression-free ...
This article is made available free of charge, as a service to our users.
Please login to access the full article, or register if you do not yet have a username and password.
Please login to access the full article, or register if you do not yet have a username and password.
